Group 1 - Hong Kong pharmaceutical stocks experienced a collective surge, with notable increases in companies such as CSPC Pharmaceutical Group and United Laboratories, both rising over 7% [1][2] - Other companies like Luye Pharma, Kelun Pharmaceutical, and Innovent Biologics also saw significant gains, with increases exceeding 6% [1][2] - The market is reacting positively to the upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting, where several innovative drug companies will showcase their research results [2] Group 2 - Analysts suggest that the Chinese innovative drug sector is entering a phase of result realization, with many research advancements expected to drive continued investment interest in the pharmaceutical sector through 2025 [3] - The collaboration between 3SBio and Pfizer regarding the PD-1/VEGF dual antibody SSGJ-707 is seen as a catalyst for Chinese innovative drug companies to accelerate integration into the global industry chain [2]